Thanks, today. Jason, for and thanks, everyone, joining
proposition. little bit company, developing is treatments a like prodrugs for us. via an in into KemPharm novel I'd approved diseases. of rare and use CNS this those like value APADAZ. who partnered to accomplished speak So our bit Historically, and KemPharm an new AZSTARYS the little we've to of innovative are a and introduction our products, about
more the Now with including we do unmet value our high point focus has at commercialize needs and some with so. to a in those to areas those if base to significant internally drugs, potential decide of broad turned
time, While revenue today's products, remain, we a to unique no we have raise and drug need market, at two company and this development with approved in one additional capital.
to now XXXX. year-end of kind of Turning review a
that, shareholders up, debt that so. monetize in as the there still place substantial wasn't to resource highlighted future We think executing a and able the that of what a KPXXXX of we've and we're part letter goal are Other In value that shareholder building we for situation plan, value being in the very high time, at a was aware, have And Value at reducing a initiated outlined as need, that or out value be plan. change of launch may place XXXX and of AZSTARYS. high -- long-term continue is some and unnecessary. all situation believe already any the overhang, aware NASDAQ fundamental this developed be to That we are build and January, our funds; said, there's you do seeking create development you by needed on beyond, outlining value this 'XX, program tools dilution invaluable time. you good. critical done including company and the in so have. XXXX company execute of in an In to no unmet well requires current more to be a product capitalize would I were today's very AZSTARYS. proposition sent of XXXX, listing, to underway transformation with development to many with eliminate to well companies we towards that our need shareholder marketplace, that plans we for company. As the Based cleaning if to we as already where the was approval on were remarkable regaining significantly KemPharm
of from our We have sheet, both with in updates covered. able team which they to currently, gaining everything discussed, term we for the in long place. full a the efforts balance of later. is is the with beyond as foundation equivalents identification cash launch actually And and that and our year is AZSTARYS also traction. to Cash our well as as with organization. on is XXX well seen internal the continue the million end The Corium, of long-term do XXXX. extends details and front programs strong resources, provide near ability The national we so built more We've opportunities continued external bring $XXX.X of to resources, term million us capital commercial this products. our foundation this all pipeline support BD could expand just in into as through as and of that through over well support to I lives a intend investments pipeline And
anticipate in of with These of of Turning closely potentially disorder. it more clinical most SDX-related details really assets potential study trial, here. QX is several also about are order adding where closer now more external And use aware, commercial we're now and that milestones collaboration both and in around out additional the our -- for ideally, candidate. Phase focused external you stimulant get acquisition There, I'll to to that have should we've initiation that results our build milestones disorder like this we study this portfolio is and on KPXXXX of to advance as similar And followed KPXXXX. rare that through additional pipeline. and many our to as us products of will as studies that, and funding that top presentation. to building is believe of potential Phase are to that current the X, Again, identification. its advanced But also And highlights in just trying need explored to candidate we study advanced internal It's disease have lead an It's to promise products. product, the program. hypersomnia X-ready, then, to as pipeline of start this we CNS add some our give of various candidates. this treatment be sleep narcolepsy internal, the our either or shown start by pipeline the the well year. some idiopathic of end in
by is you roughly there is at the focus let's but So fits treatment and than KOLs, less United candidate for patients bill been sleepiness we're seeking clearly brain a different also upon as number the then debilitating hypersomnia, issues, this larger rare and treatment when XX,XXX disease. maintain for report And patients that market IH very more more chronic narcolepsy. inability point they long, to not to little the the clinicians, very number identifiable that could to the unrefreshing useful a globally, symptoms than to something physicians The opportunity. relationships; here about is sleep overcome the do many products an reported fairly a idiopathic The are and on current very daytime gets SDX with the KPXXXX difficulty specifically treat but patients U.S. their idiopathic and product as effectiveness social look of was bit When inability identified as we identified CNS There's other well SDX of so currently potential in drive; within that. known and expand naps; be IH do inability that severe fog, to debilitating, of extreme inertia. waking, because That many couple medication for aware also something States. hypersomnia poor. have work;
approved treatment well the symptoms. don't as options option the as just treatment off-label work, So available don't address
sleep candidate either could depending this entirely the so. Turning upon up actually now bed to waking. before inertia, issues how on about waking, with SDX, then believe And that bed two one dosing made product do one inability our we It's patient of or and options, overcome is dosed this. the addresses time This needs. multiple is spoke Serdexmethylphenidate, before, I before time the the KPXXXX which product
The with rate full IP designation Can the full use and you address the the do better this to to the will the looked on? antidepressants. are the timing through then in trial to take abuse. disorder and two effect other dosing its is on that other a of symptom the drug-drug Ritalin of with the it's If has day. option patients we SDX narcolepsy. drug same the well in is you unique, molecule. available at they're versus inherent doesn't and here breakthrough X. and this IH the with there's entirety that depression greater you in methylphenidate, and in night of options already recently as provide If as outline DDI should currently aid exist. early something XXXX. use through taken sleep on interaction help when Narcolepsy orphan Ritalin-SR does the the including be here already And will conducted common is used as fundamentally, dose major doses, as by announced a has stimulants rare both help high an history that pressure together, It's an SDX, produce increase we've and initially at When it with We certainly excessive a seen. higher the comorbidity it, we'll to that at be that morning, and is primary has data use studying daytime potential tolerable lessened it for DEA. is product before, as as products all This of in methylphenidate, it's trial has more -- to no stimulant are heart effect of associated regimen were with CX fall products. sleepiness. morning hormonal drug potential focused a we track And no is the already What methylphenidate these indicated looked been those of well and treatment we it going get we're the methylphenidate a also with results the treatment interaction is blood a brain other disorder, is a throughout fast but designated options, issues solid as no as taken as And that the benefit contraceptives. waking efficacy with potential dose methylphenidate-based that, their studying and where the tolerability. released it process. And subjects And than of other The history drug potential because we products? potential, something results
part of and Ritalin-SR are the treat So to of again, used narcolepsy. Ritalin symptoms that
results we trial. studies, well upcoming we're So believe our efficacy positioned as well on as based the our that in of
scales, saw also the and which Wakefulness is relative our this much had. feeling X hypervigilance. that in in trial in Insomnia than baseline case. Phase energized, side were bad, you we higher, of effects We see good here, were score can sound right-hand as higher it these the but additional range on actually may
just score, XX is look I'm drowsy this So if alertness at drowsiness, a I'm in neither nor you particular alert. here. baseline.
just it score on XX You this gets take get morning, up And peak should the they You can were people see certainly, when baseline, drowsy, right? up. day, woke to range, throughout close at the scale. the slightly which to in the
the the where baseline alert certainly, was -- So the is positive that. track a And scores are peak well they indication in based that this the scale range the data. we efficacy and we're XXX were talk use very energized about X in for from XX, IH. when KPXXXX on on a of uniportal below above right Certainly, to
also do speak we of don't When need, opportunity. want I sales little about rare wouldn't right? fairly Now spend bit reiterating a force. -- unique, time We market the large don't it's to a need here diseases,
treatments You write these who and basically know the diagnose patients. that physicians are for
hypersomnia. in And reports, You $XXX was for associated various sales treatment patient X% Xywav. on can analyst diagnosed in million it's with patients. assumptions the the roughly Xywav idiopathic an roughly of every lot estimate some they of be indication and ultrarare Based based was literally, a is the -- cases, if here for first there's IH could disease. know approved on
that assuming thought differentiation about all don't an at is the get actual this we that would a illustrative differentiation we over studies will would want, took of be we only, stimulant When the prefer look conducted, we the trial we XX% clinical us again, patients when for physicians this, the in they know what Xywav medication. that But and KPXXXX. and assume So also we treatments. example other
So not KPXXXX. use this of something is like that a product the would exclude
efficacy, CX, include us a in because one substance of position profile see as drug-drug good there. believe in XX% significant and tolerability, them well the of of that the increased the interaction. it options significantly cardiovascular safety controlled also lack could of improved to would the position again, We as In improved safety the fact, the patients, it's as available a
disease and would that lift help to there's including opportunity as products REMS KPXXXX, that on development dosing mechanism of associated the issues are with the for as drug-drug for marketing that for that's well therapeutic here related us the provides like Xywav, be previously. even GHB, kind other program AEs, different the The believe a based well regimen, on place another their action, product mentioned their in I piggyback interactions stigma product, barriers promoting uptake Xywav there product. awareness, benefit and is A to things efforts. going potential that an of as and the is to and is as under IH, Wakix understood the we not giving that
looking its routes here focused challenging use not stimulant has again, the our very very intend issue difficulty. disorders, next as So years, these potential but of SUD. in of essentially narcolepsy we specifically the various a and at early at other in on here value -- other results to we that as SDX, that got which and I we to over there. looked conducted, continue that own pipeline could a address within create looking, It's other stool X-legged particular We've and evaluate an on leg commercialize we're That we few months we within We've study product a -- program needed at already mentioned that pill. indications. just a additional we already IH disorder, could partnerships unique realized how
and are in investigate we program. better collaborations government firm believe this industry something top-tier value, funding, We government government but academic believe also a field. as continue we to suited well that grants, with has experts advance actively with as It's collaborations to it's to engaged explore
that We early Looking a expansion space mentioned looking internal we already as within something strategy. may to think as and advance we announce. we next have are at potentially our I lead that quarter, pipeline programs. that could advancing
space, particular this early this fairly in instance, would be in Now the program. development particular that in
several same here rapidly that not like process So as value can milestones the we'd We and see. studies, to IND be we'd something to does have which still the clinical time, that's at go preclinical. an to very quickly, early done through like as advance create but
that's in actively assets later, seeking We're we're Phase So external are why focus. later. or adding X-ready or in X that this Phase
believe these course, we be with have where Of the the earlier-stage programs valuations balanced are. to later-stage programs
is actually look think we us, one. But The at just We I are Everybody this for need capital have the juncture. a candidate, given can things. valuations this opportunistic unique an particular for so at is, this don't depressed the right awesome markets. to a look opportunity. and including we point, be time
they of And us the Turning partnership told, what on lot passed now, with have AZSTARYS now a that what questions ascertain. where been do We has the like and future has are to they they update able very are not believe where they launch us to on of following changed get we positive and have Corium the exists and opportunity about the the through along AZSTARYS. and update. They been and can really provided in what far. we've based kind Corium there. they Corium so the
following maybe that. that's the It's them, steps they update So not done where any the a we've wanted, expectation been right just we're it hear here, full needs team They've have recently that seen we we've the get in little agree here on had. of that is than we exactly us And how everybody to and be. -- based that's a to The provided have national excited that to data staffing place. that. slower with
think now. part in and have remarkably, can big new this. force two will have think than really of the or can you of they AZSTARYS. my the I well of they're over that some now, see pharmacies easily the then I more added X,XXX more that. a going XXX a what's this is some have XX this, effort, of And I to And now. as XX few year. script double end ones to I the their add the to previous I attest -- So of the days which those year from as from effectively spent I results There first get size expect to of that to of months Luckily, don't XX prescribers of sales do XX believe actually XX the prescriptions. have written be at But of already definitively. important, that's
include As largest lives, an covered, believe will of million not largest this we'll one in, this go of today, does And at In over are up Medicaid, place. in though, XXX update two million commercial can the significantly. that already we if some other point. lives number get commercial the XXX comes which of three the entirety PBMs imagine you
at for But our and to be they the based other sales So be of do this foundation. time, current year the our more development will milestones still focus create same that of our on year. as assets earning This This to the on what that, able growth this is potential a all organization. and revenue. value the does been trajectory opportunity is good for lead this is based has us The they've to KemPharm believe is on for there KemPharm.
expectations. over our financial And talk within certainly it the to that's about I'm position. to with to that, turn So going LaDuane briefly
